FermaVir Announces New Preclinical Data for FV-100, Its Clinical Candidate for Shingles; Recent Data Shows Excellent Penetration and Viral Inhibition by FV-100 in Cells.

NEW YORK -- FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR), announced today that preclinical studies show that its compound for shingles inhibits viral infections exceptionally quickly and that when FV-100 is dosed orally, the active compound shows good dose dependent pharmacokinetics.

The active compound was able to inhibit the varicella zoster virus much more quickly than acyclovir, one of the frequently used and currently approved therapies for shingles. Specifically, FermaVir's compound was able to achieve an EC50 more than 20 hours sooner than acyclovir when infected cells were exposed to either drug for different periods of time. The EC50 is a measure of the amount of a compound which inhibits 50% of the virus in vitro. Significantly, an EC50 for FermaVir's compound was able to be measured at the shortest time that was tested for exposure to the compounds. Also, new preclinical oral bioavailability experiments have further confirmed previous experiments and show good linear dose dependent pharmacokinetic results.

"We are extremely pleased with the latest sets of data on FV-100. Not only does this data confirm our previous oral bioavailability data in other models but it also suggests that the properties of our compound will enhance it getting to the site of the viral infection and inhibiting the infection much faster than one of the approved drugs," said Dr. Geoffrey Henson, CEO of FermaVir.

Previous data had showed that the FermaVir compound entered cells extremely fast. This new data showed that the virus in cells is inhibited quickly as well. The new oral bioavailability data which again showed good pharmacokinetics also continues to suggest that it might be able to achieve once a day dosing, a significant benefit over current therapy.

The Company has initiated preclinical studies with its proprietary antiviral compound, currently known by its laboratory designation, FV-100, to be followed by clinical studies, as part of a long-term strategic plan for ultimate drug approval and commercialization. Research data suggests that the compound is believed to be 10,000 times more potent than currently approved drug treatments for shingles.

FV-100 is among a portfolio of FermaVir's proprietary medical technologies and clinical candidates planned for development to treat a family of viral diseases related to herpes. Among FermaVir's other lead drug candidates are powerful antiviral compounds to treat Cytomegalovirus, another potentially debilitating condition.

About FermaVir Pharmaceuticals, Inc.

FermaVir Pharmaceuticals, Inc. is an emerging biotechnology company positioned for rapid growth by developing important antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. The Company's Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is a breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. FermaVir's proprietary compound is believed to be 10,000 times more potent than currently approved shingles drug treatments. FermaVir is also developing a compound that could provide the first improved effective treatment in years for Cytomegalovirus (CMV) infection, a currently incurable viral disease from the herpes family that can threaten eyesight as well as cause severe morbidity and mortality.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although FermaVir believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Form 10K of FermaVir dated August 16, 2006,, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that FermaVir will not obtain approval to market its products, the risk that FermaVir technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.